Trial Using 125I Embedded Stent in Patients With Advanced Esophageal Cancer
Primary Purpose
Esophageal Cancer
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Esophageal stent placement
Sponsored by
About this trial
This is an interventional treatment trial for Esophageal Cancer focused on measuring Dysphagia, esophageal cancer, stent, brachytherapy
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed primary cancer of esophagus,
- Must be dysphagia caused by esophageal cancer,
- Without esophageal fistulas,
- Must be an inpatient,
- Life expectancy is over 6 months
Exclusion Criteria:
- Esophageal fistulas,
- Tracheal compression with symptoms,
- WBC <2000/mm3 and Platelet count <50,000/mm3,
- Concurrent therapies after stenting:surgery, chemotherapy,radiotherapy, Traditional Chinese Medicine
Sites / Locations
- #87 Dingjiaqiao Road
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
stenting
Arm Description
The conventional esophageal stent or 125I radiation stent is placed in the patients with dysphagia who are enrolled to the study.
Outcomes
Primary Outcome Measures
Overall survival
Secondary Outcome Measures
Quality of life
Restenosis of the stent
Dysphagia relief
Full Information
NCT ID
NCT00826813
First Posted
January 21, 2009
Last Updated
January 21, 2009
Sponsor
Southeast University, China
1. Study Identification
Unique Protocol Identification Number
NCT00826813
Brief Title
Trial Using 125I Embedded Stent in Patients With Advanced Esophageal Cancer
Official Title
Phase IV Study of Self-Expandable Esophageal Stent Loaded With 125I Seeds: a Randomized Controlled Multiple Center Trial in Patients With Advanced Esophageal Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
January 2009
Overall Recruitment Status
Unknown status
Study Start Date
January 2009 (undefined)
Primary Completion Date
March 2010 (Anticipated)
Study Completion Date
March 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Southeast University, China
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
More than half of patients with esophageal cancer are inoperable because of late stage cancer or metastasis and they have to undergo palliative treatments. Dysphagia is the major symptom of patients with inoperable esophageal cancer. To relieve the dysphagia and improve the quality of life of such patients, stent placement has been widely accepted to be an option for palliation of the symptoms. However, recurrence of the neoplastic stricture remains a challenge after stent placement. To combine the advantages of the immediate relief of the esophageal dysphagia with the stent placement and radiation therapy with brachytherapy, a novel esophageal stent loaded with 125I seeds has been developed in the authors' institute. The preliminary clinical trial in a single institute has demonstrated better results than the conventional stent. This prospective multiple center trial is designed to further demonstrate the clinical outcomes with this irradiation, stent in patients compared to those using a conventional covered stent.
Detailed Description
Esophageal cancer ranks as the fourth leading cause of death from cancer in China and sixth worldwide. Although the prognosis of surgical resection for esophageal cancer has been improved, more than 50% of such patients are inoperable and have to undergo palliative treatments because of late stage cancer or metastasis. Dysphagia is the predominate symptom of patients with inoperable esophageal cancer. To relieve the dysphagia and improve the quality of life of such patients, brachytherapy has previously been utilized. Recently, stent placement has been widely accepted to be an option for palliation of the symptoms due to the esophageal strictures. However, recurrence of the neoplastic stricture remains a challenge after stent placement. To combine the advantages of the immediate relief of the esophageal dysphagia with the stent placement and radiation therapy with brachytherapy, a novel esophageal stent loaded with 125I seeds has been developed in the authors' institute. The technical feasibility and safety with this new stent has been demonstrated to be adequate in a healthy rabbit model. The following preliminary clinical study in a single institute has demonstrated longer survival time, better quality of life and less restenosis of the stent than whose with the conventional stent. This prospective multiple center trial is designed to further demonstrate the clinical outcomes with this irradiation, stent in patients compared to those using a conventional covered stent.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Cancer
Keywords
Dysphagia, esophageal cancer, stent, brachytherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
250 (Actual)
8. Arms, Groups, and Interventions
Arm Title
stenting
Arm Type
Experimental
Arm Description
The conventional esophageal stent or 125I radiation stent is placed in the patients with dysphagia who are enrolled to the study.
Intervention Type
Device
Intervention Name(s)
Esophageal stent placement
Other Intervention Name(s)
esophageal stent implantation
Intervention Description
The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
Primary Outcome Measure Information:
Title
Overall survival
Time Frame
Death of the patient
Secondary Outcome Measure Information:
Title
Quality of life
Time Frame
3, 6, 12 months
Title
Restenosis of the stent
Time Frame
3, 6, 12 months
Title
Dysphagia relief
Time Frame
3, 6, 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed primary cancer of esophagus,
Must be dysphagia caused by esophageal cancer,
Without esophageal fistulas,
Must be an inpatient,
Life expectancy is over 6 months
Exclusion Criteria:
Esophageal fistulas,
Tracheal compression with symptoms,
WBC <2000/mm3 and Platelet count <50,000/mm3,
Concurrent therapies after stenting:surgery, chemotherapy,radiotherapy, Traditional Chinese Medicine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gao-Jun Teng, MD, Ph.D
Organizational Affiliation
Zhongda Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
#87 Dingjiaqiao Road
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210009
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
18349316
Citation
Guo JH, Teng GJ, Zhu GY, He SC, Fang W, Deng G, Li GZ. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology. 2008 May;247(2):574-81. doi: 10.1148/radiol.2472070999. Epub 2008 Mar 18.
Results Reference
background
PubMed Identifier
17085003
Citation
Guo JH, Teng GJ, Zhu GY, He SC, Deng G, He J. Self-expandable stent loaded with 125I seeds: feasibility and safety in a rabbit model. Eur J Radiol. 2007 Feb;61(2):356-61. doi: 10.1016/j.ejrad.2006.10.003. Epub 2006 Nov 7.
Results Reference
background
Learn more about this trial
Trial Using 125I Embedded Stent in Patients With Advanced Esophageal Cancer
We'll reach out to this number within 24 hrs